Physician profile
William I Lapidus
NPI 1659474435
$6,693.68
in general payments reported to CMS, 2019-2025
23 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $712 · 2021: $965 · 2022: $886 · 2023: $1,368 · 2024: $688 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.79 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,200.98 | 2019-2025 | Cabenuva, Dovato |
| Abbvie INC. | $964.68 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $834.26 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Gilead Sciences, INC. | $653.22 | 2019-2025 | Veklury, Biktarvy |
| Insmed, INC. | $498.06 | 2019-2025 | Arikayce |
| Melinta Therapeutics, LLC | $474.47 | 2019-2025 | Kimyrsa, Orbactiv, Vabomere |
| Allergan, INC. | $439.51 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $314.50 | 2020-2025 | Vibativ |
| Paratek Pharmaceuticals, INC. | $287.95 | 2020-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $188.79 | 2022-2025 | Xacduro, Zevtera, Xerava |
| Astellas Pharma US INC | $155.95 | 2019-2025 | Cresemba |
| Janssen Biotech, INC. | $154.05 | 2019-2023 | Symtuza, Stelara |
| Ferring Pharmaceuticals INC. | $149.82 | 2022-2025 | Rebyota |
| Janssen Pharmaceuticals, INC | $121.82 | 2019 | |
| Theratechnologies INC. | $63.14 | 2019-2023 | Egrifta, Trogarzo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $40.00 | 2019 | |
| Amgen INC. | $31.61 | 2023 | Evenity, Prolia |
| Tetraphase Pharmaceuticals, INC. | $28.27 | 2019-2020 | |
| Shionogi INC | $23.40 | 2022 | |
| Lilly USA, LLC | $21.53 | 2023 | |
| Octapharma USA, INC. | $17.53 | 2023 | Panzyga |
| E.R. Squibb & Sons, L.L.C. | $15.31 | 2021 | |
| Horizon Therapeutics Plc | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lapidus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.